Dolutegravir for the treatment of HIV-2 infection

摘要: Abstract Background Therapeutic options are limited for HIV-2 infected persons, largely in part due to the lack of susceptibility HIV-1 non-nucleoside reverse transcriptase inhibitors and poor some protease inhibitors. This is particularly worrisome patients with prior antiretroviral failure. Objectives Report virological response dolutegravir HIV-2-infected individuals. Study design Retrospective observational assessment all individuals treated Spain. Results From 297 recorded at Spanish national registry, 26% received therapy. Six out 8 failing on raltegravir selected integrase resistance mutations N155H (4), Y143G (1) Q148R (1). Two bearing subsequently dolutegravir. Both experienced initially more than 1.5 log drop plasma RNA significant CD4 gains. Whereas one kept undetectable viremia 6 months later, other viral rebound. Conclusion Dolutegravir may be a good therapeutic option infection, including those that previously failed